Background: Eosinophilic esophagitis (EoE) is a chronic, immune-mediated inflammatory disorder of the oesophagus that has transformed from a rarely recognized condition to one of the most common causes of dysphagia and food impaction in children and young adults. This review provides a comprehensive, clinically oriented overview of EoE for the practicing clinician.Methods: We conducted a narrative review focusing on systematic reviews, meta-analyses, randomized controlled trials and international guidelines published through 2025.Results: EoE pathogenesis involves genetic susceptibility, environmental triggers, epithelial barrier dysfunction and type 2 immune activation. Diagnosis requires clinical symptoms, endoscopic findings and histologic confirmation of >= 15 eosinophils per high-power field. Treatment options include proton pump inhibitors (histologic remission similar to 45%), swallowed topical corticosteroids (similar to 80%-93%), dietary elimination strategies (similar to 60%) and dupilumab (similar to 60%). Without treatment, EoE progresses from inflammatory to fibrostenotic disease, with stricture risk increasing approximately 5% per year of undiagnosed disease.Conclusions: EoE management requires integration of clinical, endoscopic and histologic assessments. Current treatments effectively induce remission in most patients. Future priorities include developing non-invasive monitoring tools and identifying predictors of treatment response.
Eosinophilic esophagitis: From pathophysiology to diagnosis, monitoring and treatment
Federico Caldart;
2026-01-01
Abstract
Background: Eosinophilic esophagitis (EoE) is a chronic, immune-mediated inflammatory disorder of the oesophagus that has transformed from a rarely recognized condition to one of the most common causes of dysphagia and food impaction in children and young adults. This review provides a comprehensive, clinically oriented overview of EoE for the practicing clinician.Methods: We conducted a narrative review focusing on systematic reviews, meta-analyses, randomized controlled trials and international guidelines published through 2025.Results: EoE pathogenesis involves genetic susceptibility, environmental triggers, epithelial barrier dysfunction and type 2 immune activation. Diagnosis requires clinical symptoms, endoscopic findings and histologic confirmation of >= 15 eosinophils per high-power field. Treatment options include proton pump inhibitors (histologic remission similar to 45%), swallowed topical corticosteroids (similar to 80%-93%), dietary elimination strategies (similar to 60%) and dupilumab (similar to 60%). Without treatment, EoE progresses from inflammatory to fibrostenotic disease, with stricture risk increasing approximately 5% per year of undiagnosed disease.Conclusions: EoE management requires integration of clinical, endoscopic and histologic assessments. Current treatments effectively induce remission in most patients. Future priorities include developing non-invasive monitoring tools and identifying predictors of treatment response.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.



